Mantle Cell Lymphoma: Understanding Your Pathology Report

by Rosemarie Tremblay-LeMay MD MSc FRCPC
April 16, 2026

Mantle cell lymphoma is a type of blood cancer that starts in B cells — the white blood cells that help the body fight infections by producing antibodies. It takes its name from the mantle zone, a ring of B cells that normally surrounds the germinal center within a lymph node, and it is from this zone that the abnormal cells originate.

Mantle cell lymphoma is defined by a specific genetic change — a chromosomal rearrangement involving the CCND1 gene — that causes the cells to overproduce a protein called cyclin D1, driving uncontrolled cell division. Most cases are aggressive and require treatment, though a distinct minority behaves in a slow-growing (indolent) manner. This article will help you understand the findings in your pathology report, what each term means, and why it matters for your care.

What are the symptoms of mantle cell lymphoma?

Many people with mantle cell lymphoma are diagnosed after noticing painless but progressively enlarging lumps caused by swollen lymph nodes, most often in the neck, armpits, or groin. Enlargement of the spleen — producing a feeling of fullness or discomfort in the upper left abdomen — is common. The bone marrow is frequently involved, which can cause reduced blood counts: fatigue and pallor from anemia (low red blood cells), easy bruising or bleeding from thrombocytopenia (low platelets), and increased susceptibility to infection.

Mantle cell lymphoma has a particular tendency to involve the gastrointestinal tract — the stomach, small intestine, and colon — which can cause abdominal discomfort, bleeding, diarrhea, or the appearance of multiple polyps (small growths on the bowel lining) discovered during colonoscopy. When numerous polyps are found throughout the colon and small intestine, this is called lymphomatous polyposis and is a characteristic — though not exclusive — pattern of involvement by mantle cell lymphoma. Involvement of the liver and circulating lymphoma cells in the blood (a leukemic phase) is also common in advanced disease.

General symptoms, including fever, drenching night sweats, and significant unintentional weight loss — called B symptoms — may be present, particularly in advanced disease. Because the disease often presents at an advanced stage at diagnosis, many patients have widespread involvement by the time their symptoms prompt investigation.

What causes mantle cell lymphoma?

Mantle cell lymphoma is caused by a specific chromosomal translocation — a rearrangement in which a piece of chromosome 11, carrying the CCND1 gene, breaks off and attaches to chromosome 14, next to the immunoglobulin heavy chain gene. This translocation, written as t(11;14), is found in more than 95% of cases of mantle cell lymphoma. The immunoglobulin heavy chain gene is permanently active in B cells (it drives antibody production), so when CCND1 lands next to it, cyclin D1 — the protein encoded by CCND1 — is continuously overproduced. Cyclin D1 normally acts as an “accelerator” for the cell cycle, pushing cells to divide. When it is produced at high levels without normal regulation, cells bypass the checkpoints that would normally slow or stop division, leading to uncontrolled proliferation.

This translocation alone is generally not sufficient to cause mantle cell lymphoma — additional genetic changes must accumulate over time, including mutations in genes that regulate DNA repair and cell survival. TP53 mutation (found in approximately 20–30% of cases) and deletion of the CDKN2A gene are among the most important of these secondary changes and are associated with a more aggressive disease course. No specific environmental, infectious, or lifestyle risk factor has been consistently identified. Mantle cell lymphoma is more common in older adults (median age at diagnosis is approximately 65–70) and is substantially more common in men than women (approximately 3:1). It is rare in younger people and uncommon in Asian populations.

How is the diagnosis made?

The diagnosis of mantle cell lymphoma is made by examining tissue under the microscope. A biopsy of an enlarged lymph node or other affected site is required. Excisional biopsy — removal of an entire lymph node — is preferred to provide adequate tissue for full assessment, though core needle biopsy is commonly used and is usually sufficient. When the disease presents in the gastrointestinal tract, multiple biopsies from the bowel mucosa provide the diagnostic material. Bone marrow biopsy, blood tests, and flow cytometry on blood or bone marrow are also typically performed to assess disease extent.

The pathologist examines the tissue under the microscope and performs immunohistochemistry (IHC) to identify the protein profile of the lymphoma cells, particularly cyclin D1 and SOX11, which, together with CD5 positivity, confirm the diagnosis. FISH (fluorescence in situ hybridization) for the t(11;14) translocation may be performed when the IHC results are atypical or equivocal. Once the diagnosis is confirmed, staging evaluation includes PET/CT imaging, complete blood count, LDH, and assessment of specific molecular markers, including TP53 mutation status and Ki-67 proliferation index.

What does mantle cell lymphoma look like under the microscope?

Under the microscope, most cases of mantle cell lymphoma show small to medium-sized lymphoid cells that look remarkably similar to one another — this uniformity is a diagnostically important feature. The cells have slightly irregular nuclear contours (the nucleus, which holds the DNA, has subtle indentations or irregular outlines), and the chromatin inside the nucleus is moderately dense. The cytoplasm (the material surrounding the nucleus) is scant. Mitotic figures — cells caught in the act of dividing — are present and, when numerous, indicate a more rapidly growing tumor.

The growth pattern — how the cells are arranged in the tissue — varies between cases and matters prognostically. Three main patterns are recognized:

Mantle zone pattern — The lymphoma cells grow in broad rings around residual germinal centers, mimicking the normal mantle zone but with expanded abnormal cells. This is associated with a more indolent behavior and better prognosis.
Nodular pattern — The cells form round nodular clusters without residual germinal centers—intermediate behavior.
Diffuse pattern — The cells spread uniformly through the lymph node without forming distinct clusters or mantle zones.—the most common pattern; associated with more aggressive disease.

Two morphologic variants — blastoid and pleomorphic — indicate more aggressive forms of the disease and are described below under “Subtypes and variants.”

Subtypes and variants of mantle cell lymphoma

Mantle cell lymphoma encompasses a spectrum from indolent to highly aggressive disease. The subtype and variant reported in your pathology report have important implications for prognosis and treatment approach.

Classic mantle cell lymphoma

Classic (also called conventional) mantle cell lymphoma makes up the majority of cases. It is an aggressive lymphoma that typically requires treatment at diagnosis. The cells express cyclin D1 and SOX11 (described below in the immunohistochemistry section), and the growth pattern is usually diffuse or nodular.

Indolent (leukemic non-nodal) mantle cell lymphoma

A minority of cases — estimated at 10–15% — follow a distinctly indolent (slow-growing) course. This subtype, sometimes called leukemic non-nodal mantle cell lymphoma, tends to present with circulating lymphoma cells in the blood and/or bone marrow involvement, with little or no lymph node enlargement. It is typically SOX11-negative (see IHC below) and IGHV-mutated (meaning the immunoglobulin gene shows evidence of normal B cell maturation), which are molecular features that correlate with slower growth and less aggressive behavior. Patients with this subtype are often managed with active surveillance (watch-and-wait) rather than immediate treatment, similar to the approach used in CLL/SLL. Transformation into a more aggressive disease can occasionally occur, particularly in cases with TP53 mutations.

Blastoid variant

The blastoid variant contains cells that resemble immature B cells (blasts) — they are larger than in classic mantle cell lymphoma, with more open chromatin (the nuclear material looks looser and less condensed) and a higher rate of cell division. This variant is associated with significantly more aggressive behavior than classic mantle cell lymphoma and requires intensive treatment. TP53 mutations are enriched in the blastoid variant.

Pleomorphic variant

The pleomorphic variant contains cells that vary considerably in size and shape — some may be very large with irregular nuclei. Like the blastoid variant, the pleomorphic variant is associated with aggressive behavior and a less favorable prognosis than classic mantle cell lymphoma.

Immunohistochemistry results

Immunohistochemistry (IHC) is essential for confirming the diagnosis and for distinguishing mantle cell lymphoma from other B cell lymphomas — particularly CLL/SLL and follicular lymphoma — that can look similar under the microscope. The characteristic protein profile is described below.

CD20 — Positive. Confirms B cell lineage—also the target of rituximab, the antibody used in treatment.
CD5 — Positive. CD5 co-expression with B cell markers is the first key distinguishing feature of mantle cell lymphoma. As with CLL/SLL, this separates mantle cell lymphoma from most other B cell lymphomas (follicular lymphoma, marginal zone lymphoma) that are CD5-negative. The main differential diagnosis at this point is CLL/SLL, which is also CD5-positive but differs in its other markers.
Cyclin D1 — Positive in more than 95% of cases. Cyclin D1 is the protein product of the CCND1 gene and is the single most important diagnostic marker for mantle cell lymphoma. Its overexpression due to the t(11;14) translocation is present in virtually all cases and is absent in CLL/SLL and follicular lymphoma, making it highly specific. The pathologist is looking for strong nuclear staining in most lymphoma cells.
SOX11 — Positive in the large majority of classic mantle cell lymphoma cases. SOX11 is a transcription factor (a protein that regulates gene activity) expressed in mantle cell lymphoma but not in normal B cells or most other lymphomas, making it a valuable confirmatory marker — particularly for the rare cyclin D1-negative cases. Importantly, SOX11 is typically negative in indolent (leukemic, non-nodal) mantle cell lymphoma, a key feature that identifies this subtype.
CD23 — Negative in most cases. CD23 is characteristically positive in CLL/SLL, and its absence in mantle cell lymphoma is a helpful distinguishing feature when both CD5-positive entities are being considered.
CD200 — Negative or weakly positive. CD200 is strongly expressed in CLL/SLL but is low or absent in mantle cell lymphoma, providing another distinguishing feature when the differential diagnosis includes CLL.
CD10, BCL6, LEF1 — Negative. These markers help exclude follicular lymphoma (CD10, BCL6 positive) and CLL/SLL (LEF1 positive).
Ki-67 — Variable, clinically important. Ki-67 measures the proportion of cells actively dividing. In mantle cell lymphoma, the Ki-67 proliferation index is one of the most important prognostic markers: values below 30% are associated with a more indolent behavior. In comparison, values above 30% — and especially above 50–60% — are associated with more aggressive disease and shorter survival. The Ki-67 percentage will be reported in your pathology report and is included in the MIPI prognostic score (described below).

FISH and molecular testing

FISH testing for the t(11;14) translocation — the chromosomal rearrangement that moves CCND1 next to the immunoglobulin heavy chain gene — confirms the diagnosis of mantle cell lymphoma in cases where IHC is atypical or where cyclin D1 staining is equivocal. In cases with strong, typical cyclin D1 positivity by IHC, FISH may not be necessary, though it is performed at many centers as standard practice. When cyclin D1 is negative (5% of cases), testing for SOX11 and FISH for t(11;14) and other CCND gene rearrangements (CCND2, CCND3) may establish the diagnosis.

Beyond the defining t(11;14) translocation, additional molecular testing provides important prognostic information:

TP53 mutation and 17p deletion — TP53 mutations are found in approximately 20–30% of mantle cell lymphoma cases and are one of the strongest adverse prognostic factors. Patients with TP53-mutated mantle cell lymphoma respond poorly to standard chemoimmunotherapy and require different treatment approaches, including BTK inhibitors or intensive regimens followed by transplantation. Testing for TP53 mutation (by sequencing) and 17p deletion (by FISH) is recommended before initiating therapy.
IGHV mutation status — As in CLL/SLL, the mutation status of the immunoglobulin heavy chain variable region gene (IGHV) correlates with disease behavior in mantle cell lymphoma. IGHV-mutated cases — particularly in the indolent leukemic non-nodal subtype — have a more favorable prognosis. This test may be performed as part of the molecular workup.
Complex karyotype — The presence of multiple chromosomal abnormalities beyond t(11;14) — called a complex karyotype — is associated with more aggressive disease and shorter survival.

Staging

Mantle cell lymphoma is staged using the Lugano classification (a modification of the Ann Arbor system), based on PET/CT imaging and bone marrow biopsy. Because the disease is almost always widespread at the time of diagnosis — with bone marrow, blood, and often gastrointestinal involvement — the majority of patients (approximately 70–80%) present with advanced-stage (stage III or IV) disease. However, unlike many aggressive lymphomas, the extent of anatomical spread in mantle cell lymphoma is not the primary driver of treatment decisions — molecular features (particularly TP53 status and Ki-67) and the clinical risk score (MIPI) carry more weight.

Stage I — A single lymph node region or single extranodal site is involved.
Stage II — Two or more lymph node regions on the same side of the diaphragm are involved.
Stage III — Lymph node regions on both sides of the diaphragm are involved.
Stage IV — The lymphoma has spread to one or more extranodal organs such as the bone marrow, liver, or gastrointestinal tract.

Risk stratification: the MIPI score

Prognosis in mantle cell lymphoma is estimated using the Mantle Cell Lymphoma International Prognostic Index (MIPI), which combines four factors present at diagnosis: age, performance status (ability to carry out daily activities), LDH level (a blood protein reflecting cell turnover), and white blood cell count. An enhanced version, called the MIPI-c (combined MIPI), also incorporates the Ki-67 proliferation index from the biopsy, which significantly improves its predictive accuracy.

MIPI divides patients into three risk groups:

Low risk — Median overall survival exceeding 5 years with standard treatment; some patients achieve long-term remission.
Intermediate risk — Median overall survival approximately 3–5 years.
High risk — Median overall survival approximately 1.5–3 years with standard treatment, though newer targeted therapies are improving these outcomes.

TP53 mutation status is not formally incorporated in the MIPI. Still, it is increasingly recognized as the single most important predictor of treatment resistance and outcome and is considered separately in treatment planning.

What is the prognosis?

The prognosis of mantle cell lymphoma varies substantially by subtype, molecular features, and treatment era. Classic mantle cell lymphoma is generally considered an aggressive disease that is difficult to cure with standard chemoimmunotherapy, though treatment can achieve long remissions in many patients. The median overall survival with modern treatment is approximately 5–7 years, with significant variation by risk group and molecular features. The introduction of BTK inhibitors and other targeted agents has substantially improved outcomes, particularly in relapsed or refractory disease, and ongoing clinical trials are exploring BTK inhibitor-based first-line regimens that may further improve long-term outcomes.

Patients with indolent (leukemic non-nodal) mantle cell lymphoma have a much more favorable course — many are managed without treatment for years, and median survival exceeds 7–10 years in published series. Patients with blastoid or pleomorphic variants, or with TP53 mutation, have a significantly worse prognosis than those with classic mantle cell lymphoma and favorable molecular features, with median survival below 2–3 years with standard approaches. These patients may benefit most from participation in clinical trials and intensive treatment strategies.

Achieving minimal residual disease (MRD) negativity — meaning no detectable lymphoma cells by highly sensitive testing after treatment — is increasingly recognized as an important predictor of prolonged remission in mantle cell lymphoma, particularly after intensive induction followed by autologous stem cell transplantation.

What happens after the diagnosis?

Treatment planning for mantle cell lymphoma depends on multiple factors: the subtype (classic vs. indolent), the variant (blastoid or pleomorphic), the MIPI risk score, the Ki-67 index, TP53 mutation status, and the patient’s age, fitness, and ability to tolerate intensive treatment.

For indolent (leukemic, non-nodal) mantle cell lymphoma in patients without symptoms, bone marrow failure, or rapid progression, active surveillance (watch-and-wait) is appropriate and the standard of care. Treatment is deferred until the disease causes symptoms or shows signs of progression.

For classic mantle cell lymphoma in younger, fit patients, the standard first-line approach is intensive chemoimmunotherapy followed by consolidation with autologous stem cell transplantation (harvesting the patient’s own stem cells, then returning them after intensive conditioning chemotherapy). Induction regimens typically include rituximab combined with alternating or sequential CHOP and DHAP or cytarabine-based chemotherapy (such as R-CHOP alternating with R-DHAP, or the Nordic protocol). Rituximab maintenance after transplantation prolongs remission in many patients. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are increasingly being incorporated into first-line treatment in clinical trials and are already standard for patients who are not candidates for transplantation.

For older or less fit patients with classic mantle cell lymphoma, less intensive induction regimens are used, such as bendamustine plus rituximab (BR), or VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone). Rituximab maintenance after induction is standard. BTK inhibitors (acalabrutinib, ibrutinib, zanubrutinib) are used in frontline treatment for patients with TP53-mutated disease and in relapsed or refractory disease at all ages.

For relapsed or refractory mantle cell lymphoma, BTK inhibitors are the most widely used agents, achieving response rates of 65–80% in previously treated patients. Venetoclax (a BCL2 inhibitor) is another active option, particularly in combination with BTK inhibitors. CAR T cell therapy (brexucabtagene autoleucel) is approved for relapsed or refractory mantle cell lymphoma after at least one prior line of therapy, including a BTK inhibitor.

MRD monitoring — using highly sensitive flow cytometry or PCR testing of blood or bone marrow — is increasingly used to guide treatment decisions after therapy, with MRD negativity as a treatment goal.

Questions to ask your doctor

Which subtype of mantle cell lymphoma do I have — classic or indolent — and what is the growth pattern (mantle zone, nodular, or diffuse)?
Do I have the blastoid or pleomorphic variant, and what does that mean for my treatment?
What is my Ki-67 proliferation index, and is it above or below 30%?
Was TP53 mutation and 17p deletion testing performed, and what were the results?
What is my MIPI score, and which risk group does it place me in?
Has the lymphoma spread to my bone marrow, blood, or gastrointestinal tract?
If I have the indolent subtype, am I a candidate for watch-and-wait, and how will I be monitored?
Am I a candidate for intensive treatment and autologous stem cell transplantation, and why or why not?
Will a BTK inhibitor be part of my treatment plan?
Will MRD monitoring be used to assess my response to treatment?
What happens if the lymphoma comes back? Is CAR T cell therapy an option?
Are there clinical trials I should consider?